Results 201 to 210 of about 198,039 (308)

Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES) [PDF]

Jérémie H. Lefèvre, Olivier Dubreuil, Raphaël Colle, David Tougeron, Angélique Vienot, Aurélien Dupré, Clémence Toullec, Denis Smith, Rosine Guimbaud, Benoist Chibaudel, Marie‐Line Garcia Larnicol, Dewi Vernerey, Romain Cohen   +12 more
openalex   +1 more source

Biopsy‐proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome—Retrospective single‐center cohort study

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Biopsy‐proven residual tumor at the end of chemoradiation identifies patients at high risk for disease progression. Despite achieving a delayed histologic complete response 6 weeks later, these patients show significantly worse progression‐free survival, suggesting the prognostic value of early tissue‐based response assessment during brachytherapy ...
Christoph Ebner, Ricarda Purtscheller, Barin Feroz, Jana Rieker, Linda Ebner, Mara Mantovan, Sergej Skvortsov, Mario Brüggl, Katharina Leitner, Verena Wieser, Irina Tsibulak, Christian Marth, Alain Gustave Zeimet   +12 more
wiley   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. [PDF]

CA Cancer J Clin
McKay RR, Pal S, Xie W, Aggen D, Albiges L, Apolo A, Atkins MB, Bangs R, Beckermann KE, Bellmunt J, Berg SA, Bilen MA, Braun D, Carlo MI, Efstathiou J, Galsky M, Grivas P, Gupta S, Haas N, Hakimi AA, Hammers H, Heng DYC, Hirsch M, Iyer G, Jonasch E, Koshkin VS, Kryvenko O, Lewis B, Li R, Matin S, Maughan B, McDermott DF, McGregor B, Meeks J, Milowsky M, Motzer R, Necchi A, Petrylak D, Porten S, Powles T, Rini B, Shuch B, Siefker-Radtke A, Sonpavde G, Sridhar SS, Suarez C, Tang C, Tripathi A, Van Der Heijden MS, Voss M, Xu W, Zhang T, Rosenberg J, Choueiri TK.   +53 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab

, 2021
Naoki Kadota, Nobuo Hatakeyama, Hiroyuki Hino, Michihiro Kunishige, Yoshihiro Kondo, Yoshio Okano, Hisanori Machida, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Fumitaka Ogushi, Eiji Takeuchi   +11 more
openalex   +1 more source

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

Re-defining standards of care in resectable head and neck squamous cell carcinoma-lessons from KEYNOTE-689 and NIVOPOSTOP. [PDF]

Oncologist
Mehra S, Yom SS, Burtness B.
europepmc   +1 more source